
price close busi februari
biomed devic servic
upsid aplenti surg patient adopt
look long tailwind growth
bottom line anoth except quarter total revenu growth
y/i support strong growth sensor volum offset
price pressur hardwar increas global adopt cgm on-going
uptak manag note compani
approach net activ patient global refer note
patient us call impress total underscor robust
patient growth opportun given yet meaning invest
dtc advertis see reason robust new patient addit
slow addit note demonstr strong oper
leverag first profit year compani histori
provid evid manag continu find leverag opportun despit
signific invest manufactur custom support
show impress new patient addit continu believ
market larg enough support multipl player global finger-stick test
coalesc around player manufactur focu product
pipelin profession use hospit gestat posit compani
strong line-up fulli equip lower cost technolog
cautiou near-term risk/reward set-up ahead abbott
loom clearance/launch libr like slip earli
believ fundament backdrop ww cgm market launch
medicar expect dtc advertis ramp us entri new
ou geographi support continu out-performance current level sum
remain bullish near- long-term product pipelin grow
opportun deliv upsid expect beyond buy
result announc revenu prelim revenu
origin prior pre-announc expect
consensu us sale grew y/i ou revenu
also strong y/i gm y/i om
increas y/i demonstr leverag power compani
despit continu invest sg
initi support growth beyond approv limit launch
lead broader launch earli schedul compani
focus largest ever pivot trial secondli key partnership within core
etc continu track posit lead continu new patient addit
short-term though mani patient use tndm/podd/companion product like
exist user lastli highlight ww cgm penetr remain
earli inning compani work secur access new market includ
capac constraint invest growth instal base swell
clear effort lower barrier adopt shift patient
pharmaci channel extrem success explos growth demand
system patient clinician across patient popul
said robust growth came larg backdrop suppli constraint
dynam eas compani doubl capac
continu next page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
look compani suffici suppli roll-out
medicar popul expect complet well move
forward broader dtc advertis importantli leverag
aforement infrastructur invest support launch
said invest come expens near-term headwind gm
compani also outlin plan build third manufactur facil add capac
sit closer key ou custom
opportun come focu manag repeatedli spoke
opportun see within popul within insulin-
intens popul believ approach total patient
much larger non-insulin-intens see promis earli clinic
data non-intens popul includ cost-benefit analysi
intermountain healthcar show use cgm save thousand dollar per
patient per year early-stag partner digit health
manag compani like welldoc livongo unlock valu long-
term said non-intens opportun reli lower-cost sensor
posit growth driver what reimburs
pathway remain nascent non-intens expect need addit
clinic data refin util model
guidanc chang estim
reiter revenu guidanc
growth provid gross margin guidanc non-gaap om guidanc
non-gaap adjust ebitda margin guidanc made
follow chang estim
figur summari estim revis
buy unchang target price februari
biomed devic servic
except ep newold newold newold product
high-growth med-tech comp group current trade mean
ev/sal multipl estim revenu sum increas price
target base ev/sal multipl appli revenu
estim price target assum cash
debt share outstand
figur matrix discount rate impli share price target
buy unchang target price februari
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price februari
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price februari
biomed devic servic
